Clinical trials: Prevention of Venous Thromboembolism
Venous Thromboembolism (VTE)
Acute Medically Ill VTE Prevention With Extended Duration Betrixaban Study (The APEX Study)
The purpose of this study is to evaluate whether extended prophylaxis with oral betrixaban can prevent blood clots in the leg and lung that sometime occur in patients hospitalized for an acute medical illness and to compare these…
- Trial name
- APEX (NCT01583218)
- Testing
- Betrixaban, Enoxaparin
- Where
- 462 sites in United States, Argentina and 32 more
- Volunteers
- 7,513 people
- Sponsor
- Portola Pharmaceuticals
Venous Thromboembolism
A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness
Venous Thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is associated with an increase in risk of mortality and long-term disability and is a major contributor to global disease burden.
- Trial name
- NCT05819112
- Where
- United States
- Volunteers
- 14,799 people
- Sponsor
- Sanofi
Prophylaxis of Venous Thromboembolic Events
Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery
The purpose of this study is to evaluate the safety and efficacy of two doses of TB-402 administered as a single intravenous infusion for the prevention of VTE in subjects undergoing total hip replacement surgery.
- Trial name
- NCT01344954
- Testing
- TB-402, Rivaroxaban
- Where
- 36 sites in Austria, Belgium and 7 more
- Volunteers
- 632 people
- Sponsor
- ThromboGenics
Thromboembolism
Factor Xa Inhibitor, PRT054021, Against Enoxaparin for the Prevention of Venous Thromboembolic Events (EXPERT)
Randomized study of PRT054021 40 mg and 15 mg bid vs. enoxaparin 30 mg q12h for the prophylaxis of venous thromboembolic events after unilateral knee replacement surgery.
- Trial name
- NCT00375609
- Testing
- Betrixaban, Enoxaparin
- Where
- Canada
- Volunteers
- 215 people
- Sponsor
- Portola Pharmaceuticals
High Bleeding Risk, Hemorrhage
Efficacy of Intermittent Pneumatic Compression (IPC) on Venous Thromboembolism Incidence in Intensive Care Unit (ICU) Patients With High Bleeding Risk
This multicentre open-label randomized parallel-group trial aims to evaluate the association intermittent pneumatic compression + elastick stockings versus elasting stockings alone on symptomatic or asymptomatic venous…
- Trial name
- CIREA1 (NCT00740844)
- Testing
- Intermittent pneumatic compression of the lower limbs
- Where
- 10 sites in France
- Volunteers
- 408 people
- Sponsor
- University Hospital, Brest
Thrombosis, Hip Replacement
A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery
This study is to assess if DU176b is effective in prevention of blood clots following hip replacement surgery. The duration is 7-10 days of treatment and 30 and 60 day follow-up visits.
- Trial name
- NCT00398216
- Testing
- DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
- Where
- 29 sites in United States, Canada and 5 more
- Volunteers
- 903 people
- Sponsor
- Daiichi Sankyo
Venous Thromboembolism
Eliquis (VTE Treatment and Prevention of Recurrent VTE) rPMS
To assess the real-world safety/effectiveness of Eliquis in Korean venous thromboembolism (VTE) patients and patient characteristics that are associated with bleeding among patients taking Eliquis.
- Trial name
- NCT02546817
- Where
- South Korea
- Volunteers
- 29 people
- Sponsor
- Bristol-Myers Squibb
Arthroplasty, Replacement, Thromboembolism
Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery
An observational cohort study on safety and efficacy of the 220 mg dose Pradaxa to generate additional data in predefined sub populations of patients at increased risk of bleeding or VTE
- Trial name
- NCT00846807
- Where
- 112 sites in Austria, France and 7 more
- Volunteers
- 5,476 people
- Sponsor
- Boehringer Ingelheim
Prophylaxis of Venous Thromboembolism
Rivaroxaban in Bariatric Surgery
Until now there ist no systematic investigation of the pharmacokinetic parameters of Rivaroxaban in obese patient undergoing bariatric surgery.
- Trial name
- NCT02438098
- Testing
- Rivaroxaban 10 mg
- Where
- Switzerland
- Volunteers
- 13 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Venous Thromboembolism
A Study to Evaluate Dimolegin in Prevention of Thromboembolic Complications During Knee Replacement
This study is a multicenter, double-blind, randomized, prospective phase 2 dose ranging study to evaluate the safety and efficacy of Dimolegin - DD217 in prevention of venous thromboembolic complications in patients underwent…
- Trial name
- NCT05189002
- Testing
- Dimolegin 40 mg, Dimolegin 60 mg, Fragmin
- Where
- 15 sites in Russia
- Volunteers
- 240 people
- Sponsor
- PharmaDiall Ltd.
Hip Fracture
Statin in Hip Fracture
Statins (or HMG-CoA reductase inhibitors) have largely proven their efficacy in the primary and secondary prevention of cardiovascular events.
- Trial name
- STAFF (NCT01494090)
- Testing
- Rosuvastatin
- Where
- 6 sites in France
- Volunteers
- 36 people
- Sponsor
- University Hospital, Brest
Venous Thromboembolism (VTE)
Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC)
This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have a tube placed in a vein to receive treatment (called Peripherally Inserted…
- Trial name
- ROXI-PEAK (NCT07697599)
- Testing
- REGN7508, REGN9933
- Where
- Georgia
- Volunteers
- 1,908 people
- Sponsor
- Regeneron Pharmaceuticals
Venous Thromboembolism
Abdominal Surgery Study Of GSK576428 (Fondaparinux Sodium)In Japanese Patients
This study is phase 3 study for prevention of VTE in patients with abdominal surgery.
- Trial name
- NCT00333021
- Testing
- Fondaparinux sodium, GSK576428
- Where
- 18 sites in Japan
- Volunteers
- 127 people
- Sponsor
- GlaxoSmithKline
Venous Thromboembolism, Anticoagulant
Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study)
The study aims at optimizing extended management of elderly patients (> 75 years) with at least one of the known bleeding risk factor, who suffered from first episode of venous thromboembolism of the lower extremity (proximal…
- Conditions
- Venous Thromboembolism, Anticoagulant, Elderly
- Trial name
- Jason (NCT04257487)
- Testing
- Sulodexide
- Where
- Italy
- Volunteers
- 1,455 people
- Sponsor
- Arianna Anticoagulazione Foundation
Venous Thromboembolism, Deep Venous Thrombosis
Twice Daily Enoxaparin Prophylaxis in Reconstructive Surgery Patients
Blood clots that form in the extremities (deep venous thrombosis) and lungs (pulmonary embolus) are feared complications of reconstructive surgery.
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolus
- Trial name
- NCT02687204
- Testing
- Twice daily enoxaparin prophylaxis, Real time dose adjustment
- Where
- United States
- Volunteers
- 118 people
- Sponsor
- University of Utah
Venous Thromboembolism, Thromboembolism
A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty
The objective of this study is to compare the efficacy, safety of DU-176b 30mg or DU-176b 15mg versus enoxaparin sodium for the prevention of venous thromboembolism in patients after elective total hip arthroplasty.
- Conditions
- Venous Thromboembolism, Thromboembolism, Thrombosis, Embolism and Thrombosis
- Trial name
- NCT01203098
- Testing
- DU-176b 15mg, DU-176b 30mg, Enoxaparin sodium 20 mg (=2000IU)
- Where
- 3 sites in Japan, Taiwan
- Volunteers
- 264 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Cardiovascular Diseases, Heart Diseases
Prevention of Recurrent Venous Thromboembolism (PREVENT)
A multicenter randomized, double blind placebo controlled trial to determine the efficacy of long-term, low dose warfarin in the secondary prevention of venous thromboembolism.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Peripheral Vascular Diseases, Thromboembolism
- Trial name
- NCT00000614
- Testing
- warfarin
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Thrombosis, Venous
Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)
This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).
- Trial name
- NCT00320398
- Testing
- Fondaparinux
- Volunteers
- 114 people
- Sponsor
- GlaxoSmithKline
Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients
Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort
Patients with active cancer are ~5-fold more likely to develop a venous thromboembolism (VTE) than those without. When VTE occurs, cancer patients carry an up to a 3-fold higher rate of thrombosis recurrence and ~twice the risk…
- Trial name
- OSCAR-US (NCT04979780)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), Direct Oral Anticoagulants (DOAC)
- Where
- United States
- Volunteers
- 3,708 people
- Sponsor
- Bayer
Arthritis, Osteoarthritis, Knee
Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement
The study will describe the short-term effects the study drug, rivaroxaban, has on the body when a patient is switched from enoxaparin injection (by needle) to oral rivaroxaban (by mouth) for the prevention of blood clotting in…
- Conditions
- Arthritis, Osteoarthritis, Knee, Osteoarthritis, Hip, Thromboembolism
- Trial name
- NCT01094886
- Testing
- Rivaroxaban
- Where
- 5 sites in United States
- Volunteers
- 56 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC